[go: up one dir, main page]

ZA9811180B - A method for the prevention and treatment of stunned myacardium - Google Patents

A method for the prevention and treatment of stunned myacardium

Info

Publication number
ZA9811180B
ZA9811180B ZA9811180A ZA9811180A ZA9811180B ZA 9811180 B ZA9811180 B ZA 9811180B ZA 9811180 A ZA9811180 A ZA 9811180A ZA 9811180 A ZA9811180 A ZA 9811180A ZA 9811180 B ZA9811180 B ZA 9811180B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
myacardium
stunned
phospholamban
Prior art date
Application number
ZA9811180A
Other languages
English (en)
Inventor
Heimo Haikala
Jouko Levijoki
Martti Ovaska
Petri Kaheinen
Juha Kaivola
Jarmo Pystynen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of ZA9811180B publication Critical patent/ZA9811180B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Soil Working Implements (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Road Signs Or Road Markings (AREA)
  • Processing Of Meat And Fish (AREA)
  • Fertilizers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
ZA9811180A 1997-12-12 1998-12-07 A method for the prevention and treatment of stunned myacardium ZA9811180B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99014697A 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
ZA9811180B true ZA9811180B (en) 1999-06-09

Family

ID=25535825

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811180A ZA9811180B (en) 1997-12-12 1998-12-07 A method for the prevention and treatment of stunned myacardium

Country Status (13)

Country Link
US (1) US5968959A (xx)
EP (1) EP1039884B1 (xx)
JP (1) JP2002508314A (xx)
AT (1) ATE224187T1 (xx)
AU (1) AU1565599A (xx)
BR (1) BR9813549A (xx)
CA (1) CA2311932A1 (xx)
DE (1) DE69808131T2 (xx)
DK (1) DK1039884T3 (xx)
ES (1) ES2184341T3 (xx)
PT (1) PT1039884E (xx)
WO (1) WO1999030696A1 (xx)
ZA (1) ZA9811180B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
CA2349758A1 (en) * 1998-11-02 2000-05-11 The Regents Of The University Of California A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
EP1728516A1 (en) * 1998-11-02 2006-12-06 The Regents of the University of California A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
JP2002062296A (ja) * 2000-08-22 2002-02-28 Yamaguchi Technology Licensing Organization Ltd 心不全治療薬のスクリーニング方法
DE60137778D1 (de) 2000-09-11 2009-04-09 Univ California Dominant-negativer PLB Mutant zur Behandlung der Herzerkrankungen
US7183313B2 (en) * 2002-08-23 2007-02-27 University Of Connecticut Keto cannabinoids with therapeutic indications
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
FR2970964B1 (fr) * 2011-01-28 2013-12-13 Univ Claude Bernard Lyon Nouveaux derives d'azacoumarines presentant une activite inhibitrice des pompes mdr
US9334256B2 (en) * 2011-06-15 2016-05-10 Nono Inc. Agents and methods for treating ischemic and other diseases
WO2016032569A1 (en) * 2014-08-29 2016-03-03 Celladon Corporation Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
US11730729B2 (en) 2020-07-20 2023-08-22 Neurodon Corporation Quinolines that modulate SERCA and their use for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259635A (en) * 1962-07-26 1966-07-05 Cassella Farbwerke Mainkur Ag 7-hydroxy coumarin derivative
US3515721A (en) * 1967-06-26 1970-06-02 Cassella Farbwerke Mainkur Ag 3-tertiary-aminoethyl-4-methyl or phenyl-7-ethoxycarbonylmethoxy - halo or mononitro coumarins and congeners
IT1088554B (it) * 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
IT1160365B (it) * 1978-12-19 1987-03-11 F I D I A Spa Applicazioni in campo farmacologico e terapeutico dell'8-cloro-3-(beta-dietilamincetil)-4-metil-7-etossi-carbonilmetossicumarina cloridrato preparato allo stato puro mediante procedimento selettivo, con particolare riguardo alla sua azione antiaritmica
EP1001774B1 (en) * 1997-06-25 2004-09-15 Orion Corporation Use of phospholamban inhibitors for increasing coronary flow

Also Published As

Publication number Publication date
ES2184341T3 (es) 2003-04-01
BR9813549A (pt) 2000-10-10
DK1039884T3 (da) 2002-12-09
US5968959A (en) 1999-10-19
JP2002508314A (ja) 2002-03-19
ATE224187T1 (de) 2002-10-15
WO1999030696A1 (en) 1999-06-24
DE69808131D1 (de) 2002-10-24
EP1039884B1 (en) 2002-09-18
PT1039884E (pt) 2003-01-31
CA2311932A1 (en) 1999-06-24
EP1039884A1 (en) 2000-10-04
DE69808131T2 (de) 2003-06-05
AU1565599A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
ZA9811180B (en) A method for the prevention and treatment of stunned myacardium
DE60213386D1 (de) Geldanamycinderivate zur krebsbehandlung
PT880350E (pt) Tratamento de esclerose multipla
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
GR3023537T3 (en) Inhibition of thrombin.
HU9401258D0 (en) Treatment of acne or of pseudofolliculitis barbae
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
DK85193D0 (da) Suppression of inhibitors
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
LV12353A (lv) Kruts veza profilakses metodes
ID29187A (id) Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
DE69924979D1 (de) Behandlung von chronischen schmerzen
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
AU2255201A (en) Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
MY118982A (en) Method of reducing tissue damage associated with ischemia
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
ATE312606T1 (de) Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock